Clinical Trial Update: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML [Phase 1]

View source ↗

Summary

Phase 1 trial completion reporting IO-202 as a monotherapy and IO-202 in combination with azacitidine ± venetoclax in patients with acute myeloid leukemia with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Monocytic Differentiation
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• IO-202
• Venetoclax (venetoclax)

Snippet

Sponsor: Immune-Onc Therapeutics | Conditions: AML With Monocytic Differentiation, CMML | Phase 1 | Status: COMPLETED